Pasquale N Confalone, 79303 Centennial Cir, Wilmington, DE 19807

6399784, Jun 4, 2002

Jan 10, 2001

09/757459

Philip Ma - Chadds Ford PA
Pasquale N. Confalone - Wilmington DE
Hui-Yin Li - Newark DE

Bristol-Myers Squibb Pharma Company - Princeton NJ

C07D26102

548240, 548247, 548131, 558375, 564163, 564244, 564246

The present invention relates to processes for the conversion of nitrites to amidines in the preparation of compounds which are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex. The compounds described herein are potent thrombolytics and useful for the inhibition of platelet aggregation in the treatment of thromboembolic disorders.

6465656, Oct 15, 2002

Dec 3, 2001

10/005938

Jiacheng Zhou - Hockessin DE
Lynette May Oh - West Chester PA
Pasquale N. Confalone - Greenville DE
Hui-Yin Li - Hockessin DE
Philip Ma - West Chester PA

Bristol-Myers Squibb Pharma Company - Princeton NJ

C07D26120

548241, 5413697

A novel process for making 1,3,5-trisubstituted pyrazoles of the type shown below from appropriate phenyl hydrazines is described. These compounds are useful as factor Xa inhibitors.

6541639, Apr 1, 2003

Jul 25, 2001

09/912950

Jiacheng Zhou - Hockessin DE
Pasquale N. Confalone - Greenville DE
Hui-Yin Li - Hockessin DE
Philip Ma - West Chester PA
Lynette M. Oh - West Chester PA
Lucius T. Rossano - Landenberg PA
Charles G. Clark - Cherry Hill NJ
Chris Teleha - Bear DE

Bristol-Myers Squibb Pharma Company - Princeton NJ

C07D21102

546249, 546250, 5462741, 548255, 5482658, 5483435, 548563

The present invention provides of method of preparing phenyl-substituted azoles. This method uses an efficient ligand-accelerated Ullmann coupling reaction of anilines with azoles. The coupling products are useful for preparing factor Xa inhibitors.

6562963, May 13, 2003

Jul 31, 2001

09/919564

Roberta L. Dorow - Portage MI, 49024
Silvio Campagna - New Castle DE, 19720
Pasquale N. Confalone - Greenville DE, 19807
Fuqiang Jin - Wilmington DE, 19810
Zhe Wang - Hockessin DE, 19707

C07C23101

540456, 544168, 560169, 560172, 564135, 564136, 564139, 564143, 564153, 564158, 564159, 564205, 564207, 564208

The present invention is directed to a process for the preparation of a compound of formula (X-a) or a pharmaceutically acceptable salt form thereof, wherein: R is selected from the group consisting of: C alkyl substituted with 0-5 R , â(CH ) âC cycloalkyl substituted with 0-5 R , and â(CH ) -aryl substituted with 0-5 R. Compounds of Formula (X-a) are macrocyclic molecules containing anti-succinate residues which inhibit metalloproteinases such as aggrecanase, and the production of tumor necrosis factor (TNF). The anti-succinates are formed by an Ireland Claisen rearrangement of a silyl ketene acetal which proceeds with high stereoselectivity.

6610858, Aug 26, 2003

Apr 25, 2002

10/132233

Philip Ma - West Chester PA
Pasquale N. Confalone - Wilmington DE
Hui-Yin Li - Hockessin DE

Bristol-Myers Squibb Pharma Company - Princeton NJ

C07D26102

548240, 548247

The present invention relates to processes for the conversion of nitriles to amidines in the preparation of compounds which are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex. The compounds described herein are potent thrombolytics and useful for the inhibition of platelet aggregation in the treatment of thromboembolic disorders.

6770763, Aug 3, 2004

Mar 14, 2003

10/389528

Nicholas A. Magnus - Indianapolis IN
Pasquale N. Confalone - Greenville DE
Scott A. Savage - Yardley PA
Matthew Yates - Lafayette IN
Robert E. Waltermir - Hillsborough NJ
David J. Meloni - Bear DE
Silvio Campagna - Candia NH

Bristol-Myers Squibb Company - Princeton NJ

C07D20704

548550, 548551, 502333, 5462484

A novel process for the asymmetric synthesis of an amino-pyrrolidinone of the type shown below from appropriate pyrrolidinones is described. These compounds are useful as intermediates for MMP and TACE inhibitors.

6919451, Jul 19, 2005

Dec 3, 2002

10/308741

Jiacheng Zhou - Hackessin DE, US
Lynette M. Oh - West Chester PA, US
Philip Ma - West Chester PA, US
Hui-Yin Li - Hockessin DE, US
Pasquale Confalone - Greenville DE, US

Bristol-Myers Squibb Company - Princeton NJ

C07D471/04

544127, 544333, 544405, 546119, 546120

A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones of the type shown below from appropriate phenyl hydrazines is described. These compounds are useful as factor Xa inhibitors.

6927291, Aug 9, 2005

Mar 1, 2002

10/087112

Fuqiang Jin - Wilmington DE, US
Pasquale N. Confalone - Greenville DE, US

Pharmasset, Ltd. - Tucker GA

C07D405/04

544317

An efficient synthetic route to antiviral 2′,3′-dideoxy-2′,3′-didehydro-nucleosides, such as 2′,3′-dideoxy and 2′- or 3′-deoxyribo-nucleoside analogs, from available precursors is disclosed, with the option of introducing functionality as needed. In one embodiment, a method for the preparation of β-D and β-L-2′,3′-dideoxy-2′,3′-didehydro-nucleosides is described that includes: activating a compound of structure (1) wherein B is a pyrimidine or purine base and Y is O, S or CHwith an acyl halide of the formula X—C(═O)R, X—C(═O)C(R)OC(═O)Ror X—C(═O)OR(wherein X is a halogen, and each Ris independently hydrogen, lower alkyl, alkyl, aryl or phenyl); reducing the resulting compound with a reducing agent to form a 2′,3′-dideoxy-2′,3′-didehydro-nucleoside; and optionally deprotecting the nucleoside. The haloacylation of the first step can form the 2′-acyl-3′-halonucleoside, the 3′-acyl-2′-halonucleoside, or a mixture thereof.